Is Glaukos Stock (GKOS) Halal? A Complete Analysis

The Short Answer

Glaukos stock (GKOS) is generally considered halal by most Islamic scholars and Sharia screening criteria, subject to financial-screen verification. Glaukos is an ophthalmic medical-technology and pharmaceutical company.

Medical-device and pharmaceutical-therapy development is unambiguously permissible — and indeed beneficial — at the activity level. The principal consideration is the financial screen: Glaukos has issued convertible debt to fund its pipeline and is not yet consistently profitable, so the leverage and liquidity ratios should be verified at the time of investment.

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

Glaukos' Business Activity

Glaukos develops and sells:

• Glaucoma devices: Micro-invasive glaucoma-surgery (MIGS) implant devices
• Corneal health: Cross-linking therapy for keratoconus and corneal disorders
• Pharmaceutical pipeline: Drug-delivery and pharmaceutical candidates for eye disease

These are general-purpose healthcare and medical-technology businesses — developing devices and therapies that treat eye disease. This is permissible at the activity level.

Concerns to Be Aware Of

1. Leverage and Convertible Debt

Glaukos has issued convertible debt to fund its R&D pipeline. The debt-to-market-cap ratio should be verified against the 33% threshold at the time of investment, and convertible instruments warrant particular attention. This is the primary Sharia-screening consideration.

2. Liquidity and Interest-Income Ratios

Glaukos maintains a sizable cash-and-investments position relative to its still-growing revenue base. The interest-income and liquidity ratios should be checked against the relevant thresholds, and the investment portfolio confirmed to be in Sharia-acceptable instruments.

3. Emerging-Growth Profile

Glaukos is an emerging-growth company that is not yet consistently profitable, reinvests heavily in R&D, and depends on regulatory approvals and clinical-trial outcomes. The stock can be highly volatile. These are business, regulatory, and valuation considerations rather than Sharia screen concerns.

Financial Ratios (2025)

Based on Glaukos' most recent financial statements:

• Total Debt / Market Cap: Verify against 33% threshold — convertible debt warrants attention ✅/⚠️
• Interest Income / Revenue: Verify against 5% threshold — sizable cash position ✅/⚠️
• Haram Revenue: Negligible (medical technology) ✅
• Business Activity: Permissible medical-technology and pharmaceutical development ✅

Verdict from Major Screening Agencies

Glaukos stock is generally screened as compliant (halal) with purification by:

• Zoya App — Compliant with purification (verify leverage and liquidity) ✅
• MSCI Islamic criteria — Generally included subject to ratios ✅
• Most major Sharia advisory boards — Compliant with purification of small interest income ✅

Bottom Line

Glaukos (GKOS) is generally halal with purification for Muslim investors, subject to financial-screen verification. The core business — ophthalmic devices and pharmaceutical therapies — is unambiguously permissible at the activity level. The main step is verifying the leverage and liquidity ratios at the time of investment, paying particular attention to the convertible debt.

For Muslim investors seeking medical-technology exposure, GKOS sits alongside other halal-screened names like Inspire Medical (INSP) and Edwards Lifesciences (EW).